AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8067226 — intervention group
Group type: COMPARATOR
Intervention: Noncoated equipment with full heparinization (3 mg.kg‐1)
Number of subjects: 20
Study 8067226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 3377061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydron zero‐6 lenses (38% nominal water content)
Number of subjects: 9
Study 3377061 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocurve II lenses (55% nominal water content)
Number of subjects: 9
Study 3377061 — intervention group
Group type: EXPERIMENTAL
Intervention: Permalens contact lenses (71% nominal water content)
Number of subjects: 9
Study 30608613 — intervention group
Group type: EXPERIMENTAL
Intervention: Chosen by the proposer (choice mode)
Number of subjects: 0
Study 30608613 — intervention group
Group type: COMPARATOR
Intervention: Random pairing mode (computer selection)
Number of subjects: 0
Study 30608613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fair offers
Number of subjects: 0
Study 30608613 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfair offers to rivals
Number of subjects: 0
Study 30608613 — intervention group
Group type: EXPERIMENTAL
Intervention: Offers received by participants
Number of subjects: 0
Study 30608613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivals receiving fair shares after being chosen by the proposer
Number of subjects: 0
Study 27505301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Therapy (ST) 10-day
Number of subjects: 341
Study 27505301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Therapy (ST) 14-day
Number of subjects: 341
Study 27505301 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant Therapy (CT) 10-day
Number of subjects: 341
Study 27505301 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant Therapy (CT) 14-day
Number of subjects: 341
Study 25129681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (2 mg/kg first dose, followed by 2 mg/kg/d in 2 divided doses for 3 days)
Number of subjects: 79
Study 25129681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 79
Study 25129681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 23312076 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA dietary portfolio
Number of subjects: 16
Study 21067319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie-assisted intubation (BAI)
Number of subjects: 35
Study 21067319 — intervention group
Group type: COMPARATOR
Intervention: Traditional endotracheal intubation (ETI)
Number of subjects: 35
Study 18806939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM)
Number of subjects: 72
Study 18806939 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard technique with endoscope magnification)
Number of subjects: 72
Study 16448970 — intervention group
Group type: EXPERIMENTAL
Intervention: Study diagnosis of COPD based on spirometric results (FEV(1)/FVC < 0.70)
Number of subjects: 597
Study 16448970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior diagnosis of asthma
Number of subjects: 597
Study 16448970 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior diagnosis of chronic bronchitis or emphysema (CBE)
Number of subjects: 597
Study 16448970 — intervention group
Group type: EXPERIMENTAL
Intervention: No prior diagnosis of obstructive lung disease
Number of subjects: 597
Study 15645955 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 97
Study 15645955 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 97
Study 15645955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 97
Study 15645955 — intervention group
Group type: COMPARATOR
Intervention: Diet and Exercise
Number of subjects: 97
Study 11709454 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment from a physiotherapist in primary care for 12 weeks
Number of subjects: 201
Study 11709454 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment from general practitioner including patient education and drug treatment if necessary)
Number of subjects: 201
Study 9046220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cholangiography (IVC)
Number of subjects: 100
Study 9046220 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative cholangiography (IOC)
Number of subjects: 100
Study 7943088 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose dexamethasone (10 mg intravenously every 12 hours until delivery)
Number of subjects: 25
Study 7943088 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 25
Study 29752332 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/day
Number of subjects: 0
Study 29752332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27482615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate (ALN) 70 mg weekly
Number of subjects: 60
Study 27482615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 5 mg once yearly
Number of subjects: 60
Study 24342462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.15 mg/kg in a 10‐minute bolus followed by continuous infusion of 6 μg/kg per minute until the end of rTMS)
Number of subjects: 12
Study 24342462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 22154037 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based group intervention (two sessions of health education 5 weeks apart)
Number of subjects: 400
Study 22154037 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-help material only)
Number of subjects: 400
Study 19696679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 0.5 mg kg(‐1)
Number of subjects: 250
Study 19696679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 mg kg(‐1)
Number of subjects: 250
Study 19696679 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 2 mg kg(‐1)
Number of subjects: 250
Study 19696679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg kg(‐1)
Number of subjects: 250
Study 19696679 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 250
Study 18212092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHOEP-14
Number of subjects: 139
Study 18212092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-CHOEP-21
Number of subjects: 139
Study 16574783 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult ASPD Only
Number of subjects: 178
Study 16574783 — intervention group
Group type: EXPERIMENTAL
Intervention: Full ASPD
Number of subjects: 178
Study 16574783 — intervention group
Group type: COMPARATOR
Intervention: No CD/ASPD
Number of subjects: 178
Study 16574783 — intervention group
Group type: COMPARATOR
Intervention: CD Only
Number of subjects: 178
Study 12749492 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 1890
Study 11128888 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycra garments worn for 3 hours
Number of subjects: 16
Study 8990654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy (PR)
Number of subjects: 20
Study 8990654 — intervention group
Group type: COMPARATOR
Intervention: Scleral buckling (SB)
Number of subjects: 20
Study 1450096 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (2 mg/kg body weight)
Number of subjects: 10
Study 1450096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-N-dealkylated disopyramide (2 mg/kg body weight)
Number of subjects: 10
Study 1450096 — intervention group
Group type: COMPARATOR
Intervention: Atropine (0.04 mg/kg)
Number of subjects: 10
Study 6419640 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV) at operating pressures of 1.3, 1.8, and 2.3 bars.
Number of subjects: 15
Study 6419640 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV) at increasing operating pressures.
Number of subjects: 15
Study 6419640 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV) at operating pressures.
Number of subjects: 15
Study 6419640 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating pressure during HFJV.
Number of subjects: 15
Study 31528850 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way mobile phone intervention plus standard of care (MPI + SOC)
Number of subjects: 521
Study 31528850 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care alone (SOC)
Number of subjects: 521
Study 29485388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A
Number of subjects: 175
Study 29485388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B
Number of subjects: 175
Study 29485388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 175
Study 26865162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance Commitment Therapy (up to eight sessions, each 1 hour)
Number of subjects: 54
Study 26865162 — intervention group
Group type: COMPARATOR
Intervention: Talking control
Number of subjects: 54
Study 26865162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance Commitment Therapy
Number of subjects: 54
Study 25210836 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mass azithromycin treatment (3 distributions)
Number of subjects: 1034
Study 25210836 — intervention group
Group type: COMPARATOR
Intervention: Biannual mass azithromycin treatment (6 distributions)
Number of subjects: 1034
Study 22682095 — intervention group
Group type: EXPERIMENTAL
Intervention: PINCER intervention (pharmacist-led information technology-enabled intervention)
Number of subjects: 82
Study 20207412 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clusters (women's groups)
Number of subjects: 36113
Study 20207412 — intervention group
Group type: COMPARATOR
Intervention: Control clusters (no women's groups)
Number of subjects: 36113
Study 18067628 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times per week for 16 weeks
Number of subjects: 43
Study 18067628 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied three times per week for 16 weeks
Number of subjects: 43
Study 15952199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 300 mg/day
Number of subjects: 178
Study 15952199 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20-40 mg/day
Number of subjects: 178
Study 15952199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 15952199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 178
Study 11923046 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (700 mg) administered four times daily during TD-GTN therapy
Number of subjects: 14
Study 11923046 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules administered four times daily during TD-GTN therapy
Number of subjects: 14
Study 9811376 — intervention group
Group type: EXPERIMENTAL
Intervention: 33 microM capsaicin
Number of subjects: 0
Study 9811376 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 microM capsaicin
Number of subjects: 0
Study 9811376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent stimulation with capsaicin
Number of subjects: 0
Study 9811376 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin in candy formulation
Number of subjects: 0
Study 9811376 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthened inter-stimulus interval (ISI) with intermittent stimulation
Number of subjects: 0
Study 7666103 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1,600 mg/d (n = 27)
Number of subjects: 55
Study 7666103 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (n = 28)
Number of subjects: 55
Study 2564949 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant pro-urokinase (rscu-PA) 80 mg (20 mg bolus followed by 60 mg infusion for 60 min)
Number of subjects: 401
Study 2564949 — intervention group
Group type: COMPARATOR
Intervention: streptokinase 1.5 million IU infused over 60 min
Number of subjects: 401
Study 2564949 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant pro-urokinase (rscu-PA)
Number of subjects: 401
Study 2564949 — intervention group
Group type: COMPARATOR
Intervention: streptokinase
Number of subjects: 401
Study 401690 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN), mean dose 29 mg
Number of subjects: 21
Study 401690 — intervention group
Group type: COMPARATOR
Intervention: Sublingual placebo
Number of subjects: 21
Study 31843833 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase progesterone supplementation from early luteal phase until gestational age 8 weeks
Number of subjects: 604
Study 31843833 — intervention group
Group type: COMPARATOR
Intervention: No luteal phase progesterone supplementation
Number of subjects: 604
Study 31843833 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst warming and transfer on day 6 after ovulation trigger
Number of subjects: 604
Study 31843833 — intervention group
Group type: COMPARATOR
Intervention: Blastocyst warming and transfer on day 7 after ovulation trigger
Number of subjects: 604
Study 28387798 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM
Number of subjects: 63
Study 28387798 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 63
Study 28387798 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 63
Study 28387798 — intervention group
Group type: COMPARATOR
Intervention: Pooled ART (IVM, IVF, ICSI)
Number of subjects: 63
Study 28387798 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous conception
Number of subjects: 63
Study 25739642 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga and meditation intervention
Number of subjects: 40
Study 25739642 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 23573878 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal hernia repair (LIHR)
Number of subjects: 252
Study 23573878 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein tension‐free hernia repair
Number of subjects: 252
Study 23573878 — intervention group
Group type: COMPARATOR
Intervention: TAPP repair
Number of subjects: 252
Study 23573878 — intervention group
Group type: COMPARATOR
Intervention: TEP repair
Number of subjects: 252
Study 22010915 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier-ART group (ART initiated within 4 weeks after the start of tuberculosis treatment, 214 patients)
Number of subjects: 642
Study 22010915 — intervention group
Group type: COMPARATOR
Intervention: Later-ART group (ART initiated during the first 4 weeks of the continuation phase of tuberculosis treatment, 215 patients)
Number of subjects: 642
Study 22010915 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier-ART group
Number of subjects: 642
Study 22010915 — intervention group
Group type: COMPARATOR
Intervention: Later-ART group
Number of subjects: 642
Study 22010915 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CD4+ T-cell counts of less than 50 per cubic millimeter
Number of subjects: 642
Study 20151522 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rocuronium
Number of subjects: 0
Study 20151522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative fractional doses of rocuronium
Number of subjects: 0
Study 20151522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose of 400 microg-Kg(‐1) of rocuronium
Number of subjects: 0
Study 16675783 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 60
Study 16675783 — intervention group
Group type: COMPARATOR
Intervention: VATS
Number of subjects: 60
Study 12855209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening module (intervention)
Number of subjects: 530
Study 12855209 — intervention group
Group type: COMPARATOR
Intervention: Physical activity module (control)
Number of subjects: 530
Study 10863856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 1,200 mg/day for 24 weeks
Number of subjects: 25
Study 10863856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9197874 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal Replacement Therapy (HRT)
Number of subjects: 73
Study 9197874 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined HRT
Number of subjects: 73
Study 9197874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential HRT
Number of subjects: 73
Study 9197874 — intervention group
Group type: COMPARATOR
Intervention: Placebo/untreated
Number of subjects: 73
Study 1332094 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPP (0.35 mg/kg)
Number of subjects: 39
Study 1332094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3547757 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1600 micrograms/day)
Number of subjects: 28
Study 3547757 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (1500 micrograms/day)
Number of subjects: 28
Study 31609137 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing sugarless gum every 2 hours for 15 minutes starting at the second postoperative hour
Number of subjects: 109
Study 31609137 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (Control group)
Number of subjects: 109
Study 31609137 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing sugarless gum
Number of subjects: 109
Study 31022328 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 6190
Study 31022328 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 6190
Study 26797808 — intervention group
Group type: EXPERIMENTAL
Intervention: New pharmacokinetic model for hydromorphone during TCI-PCA
Number of subjects: 50
Study 26797808 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient controlled analgesia (PCA)
Number of subjects: 50
Study 26409014 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG) implant
Number of subjects: 2982
Study 26409014 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 2982
Study 26409014 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD (TCu380A)
Number of subjects: 2982
Study 24119351 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day live, expert-led educational session
Number of subjects: 403
Study 24119351 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced DVD with similar content
Number of subjects: 403
Study 24119351 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 403
Study 22208901 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 62
Study 22208901 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (subsequent use after etomidate)
Number of subjects: 62
Study 22208901 — intervention group
Group type: COMPARATOR
Intervention: Control (no etomidate)
Number of subjects: 62
Study 18082737 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin tablets
Number of subjects: 0
Study 18082737 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate tablets
Number of subjects: 0
Study 18082737 — intervention group
Group type: COMPARATOR
Intervention: Metformin dosing compliance
Number of subjects: 0
Study 15843631 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pulse transcranial magnetic stimulation (TMS) to the right frontal eye field (FEF)
Number of subjects: 0
Study 15843631 — intervention group
Group type: COMPARATOR
Intervention: Single pulse transcranial magnetic stimulation (TMS) to a right posterior control site
Number of subjects: 0
Study 12921333 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 160
Study 11406744 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse drug reactions observed by general practitioners
Number of subjects: 254
Study 9003851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at a dosage of 15 mg/kg per day, increased to 30 mg/kg per day if necessary
Number of subjects: 19
Study 8216015 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.006% PhXA41
Number of subjects: 40
Study 8216015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3315586 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC) 30U
Number of subjects: 10
Study 3315586 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase 1,500,000U
Number of subjects: 10
Study 3315586 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 10
Study 3315586 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 10
Study 3315586 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC and Streptokinase
Number of subjects: 10
Study 29248433 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self-guided breathing retraining intervention (DVD plus printed booklet)
Number of subjects: 655
Study 29248433 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face breathing retraining sessions
Number of subjects: 655
Study 29248433 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 655
Study 29248433 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (DVDB, face-to-face, and usual care)
Number of subjects: 655
Study 26940689 — intervention group
Group type: EXPERIMENTAL
Intervention: oral morphine
Number of subjects: 520
Study 26940689 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone
Number of subjects: 520
Study 26940689 — intervention group
Group type: EXPERIMENTAL
Intervention: transdermal fentanyl
Number of subjects: 520
Study 26940689 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 520
Study 24712653 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of a standardized ginger extract per day (300 mg per capsule, administered q.i.d for five days during the first three cycles of chemotherapy)
Number of subjects: 0
Study 24712653 — intervention group
Group type: COMPARATOR
Intervention: Standard anti-emetic therapy (placebo)
Number of subjects: 0
Study 24712653 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of a standardized ginger extract per day
Number of subjects: 0